Home - CVMD - Dysmetabolic Disease - Dyslipidemia

PriMed Non-Human Primate Model of Dyslipidemia and Atherosclerosis


Nonhuman primates are phylogenetically similar to humans including in lipid metabolism and lipid profiles. All humans and NHPs are susceptible to the development of diabetes and dyslipidemia from middle age.



Primed Shines Spontaneous Dyslipidemia NHP Capability


Breeding center: n=~3000 rhesus macaques (macaca mulatta).
Colony of n=~700 dysmetabolic rhesus macaques.
Historical clinical /metabolic data (7yrs.)
Semiannual metabolic screenings.
Plasma and tissue biobank.
All stages of metabolic diseases.


Benchmark Study: 

PCSK9 inhibitor, Ezetimibe and statins have been validated with our dyslipidemia NHP model.
Metabolic biomarker assay development and validation (HMG-COA reductase inhibitors, PCSK9 inhibitors, NPC1L1).
More than 40 compounds have been performed for a dozen international and domestic clients.



      


      


                                           


PriMed Posters and Publications


ADA 77th Scientific Sessions, San Diego

2427-PUB: Determination and Evaluation of Hypertension in a Nonhuman Primate Model of Type 2 Diabetes

1993-P: Adaptation of Slow- and Fast-twitch Skeletal Muscles to Type 2 Diabetes Mellitus (T2DM) in Diabetic Rhesus Monkeys: an Initial Experience with Non-contrast MRI Microcirculation Mapping Techniques.


2017 Keystone Symposium on Bile Acid Receptors as Signal Integrators in Liver and Metabolism, Monterey 

Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Nonhuman Primates (NHP’s) is Comparable to Humans for Metabolic Features, Histology and Imaging


ICO 2016, Vancouver

Diagnosis Of Naturally-occurring Non-alcoholic Steatohepatitis (NASH) In Obese Rhesus Monkeys Using Histopathology Criteria

Quantification Of Hepatic Fat In Naturally-occurring Nonalcoholic Fatty Liver Disease (NAFLD) In Obese Rhesus Monkeys Using Dual-energy CT (DECT)


ADA 75th Scientific Sessions, Boston

2891-PO: The Characteristics of Blood Pressure of Type 2 Diabetic Monkeys

2122-P: Effects of a Long-Acting Formulation of Exenatide on Glucose and Weight Control in Type 2 Diabetic Rhesus Monkeys


More information about posterand publications                                               


Contact Us Right Now

Email : bd@scprimed.com

Tel : +86-28-85921823

Fax : +86-28-62491302

Zip code : 610041

Address : Floor 5, Incubator B4,Tianfu Life & Science Park, No. 88 Southern Keyuan Road,High-tech Zone, Chengdu, Sichuan, China, 610041


Private Plicy